Literature DB >> 31943059

Pneumonia of unknown aetiology in Wuhan, China: potential for international spread via commercial air travel.

Isaac I Bogoch1,2, Alexander Watts3,4, Andrea Thomas-Bachli3,4, Carmen Huber3,4, Moritz U G Kraemer5,6, Kamran Khan1,3,4.   

Abstract

There is currently an outbreak of pneumonia of unknown aetiology in Wuhan, China. Although there are still several unanswered questions about this infection, we evaluate the potential for international dissemination of this disease via commercial air travel should the outbreak continue. © International Society of Travel Medicine 2020. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  SARS; air travel; coronavirus; outbreak; pneumonia; zoonosis

Mesh:

Year:  2020        PMID: 31943059      PMCID: PMC7107534          DOI: 10.1093/jtm/taaa008

Source DB:  PubMed          Journal:  J Travel Med        ISSN: 1195-1982            Impact factor:   8.490


On 30 December 2019, a report of a cluster of pneumonia of unknown aetiology was published on ProMED-mail, possibly related to contact with a seafood market in Wuhan, China. Hospitals in the region held an emergency symposium, and support from federal agencies is reportedly helping to determine the source of infection and causative organism. The seafood market has since been closed, but purportedly sold a variety of live animal species. On 5 January 2019, the World Health Organization (WHO) published a document outlining their request for more information from Chinese public health authorities, and detailed 44 patients had ‘pneumonia of unknown aetiology’, with 121 close contacts under surveillance (www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/). The WHO reported that 11 patients were severely ill, and many affected individuals had contact with the Huanan Seafood market. Some patients were reported to have fever, dyspnea and pulmonary infiltrates on chest radiography. At the time of publication, limited information has been produced directly by Chinese public health authorities; however, media reports documenting interviews with such authorities have stated that the aetiology is not yet identified, that there are now 59 affected patients, and that severe acute respiratory syndrome (SARS), the Middle East respiratory syndrome (MERS), avian influenza and several other common respiratory pathogens have been ruled out (http://news.hebei.com.cn/system/2020/01/05/100154729.shtml). On 8 January 2019, news outlets and ProMED-mail reported that genetic sequencing demonstrated a novel coronavirus as the potential causative organism. Given the recent history of zoonotic transmission of a coronavirus emerging from a live-animal market in China in 2002, and the potential for novel pathogens to rapidly spread globally via commercial air travel,, we sought to evaluate international travel patterns from Wuhan, China in order to anticipate patterns of disease dispersion should this outbreak evolve. Top 20 passenger destination cities from Wuhan, China, January–March 2018 and corresponding IDVI of destination countries *2018 estimates (The UN). **IDVI value estimated for China. ***IATA data between January and March 2018, inclusive. SAR, Special Administrative Region. We evaluated 2018 travel data generated from the International Air Transport Association (IATA) to quantify passenger volumes originating from the international airport in Wuhan, China, between January and March, inclusive. IATA data accounts for ~90% of passenger travel itineraries on commercial flights, excluding transportation via unscheduled charter flights (the remainder is modelled using market intelligence). These data represent direct origin (Wuhan) to destination trips, and indirect trips that originated in Wuhan, but had connecting flights to a final destination. We also report Infectious Disease Vulnerability Index (IDVI) scores for countries receiving significant numbers of travellers from Wuhan. The IDVI score is a validated tool to estimate a country’s capacity to prepare for and manage infectious disease threats. The score is based on metrics from the following seven domains: demographic, health care, public health, disease dynamics, political (domestic), political (international) and economic. Countries are scored between 0 and 1 with higher scores representing greater capacity to respond to outbreaks. Table 1 outlines the top 20 destination cities with passengers arriving from Wuhan, Bangkok, Hong Kong, Tokyo and Taipei received the largest volumes with 41 080, 23 707, 20 001 and 17 645 arrivals between January and March, respectively. The IDVI for these leading destinations all exceed 0.65. Sydney and Victoria, Australia and Dubai, UAE are the only three cities in the top 20 destinations that are outside of Asia. Bali, Indonesia has the lowest IDVI score (0.563) in the top 20 destination cities.
Table 1

Top 20 passenger destination cities from Wuhan, China, January–March 2018 and corresponding IDVI of destination countries

Destination cityPopulation* (in millions)Destination provinceDestination countryIDVIDirect volume***Total volume***
Bangkok8.28Bangkok MetropolisThailand0.71138 45741 080
Hong Kong7.39Hong Kong SARHong Kong SAR0.664**23 60823 707
Tokyo9.27TokyoJapan0.92618 58120 001
Taipei2.62TaipeiTaiwan0.71015 08617 645
Phuket0.39PhuketThailand0.71114 09716 656
Seoul9.78SeoulKorea (South)0.87911 77113 727
Singapore5.61SingaporeSingapore0.878859913 123
Kota Kinabalu0.25SabahMalaysia0.76112 34012 661
Macau0.62Macau SARMacao SAR0.664**10 91810 932
Denpasar Bali0.79BaliIndonesia0.56377599065
Sydney5.23New South WalesAustralia0.91350938431
Dubai3.14DubayThe UAE0.76563897389
Kuala Lumpur1.81WP Kuala LumpurMalaysia0.76123936822
Kaohsiung2.77Kaohsiung CityTaiwan0.71063736617
Osaka2.69OsakaJapan0.92630625745
Krabi0.46KrabiThailand0.71150125718
Melbourne4.94VictoriaAustralia0.91305648
Surat Thani0.13Surat ThaniThailand0.71150445624
Chiang Mai0.13Chiang MaiThailand0.71143545293
Penang1.77Pulau PinangMalaysia0.76144365059

*2018 estimates (The UN).

**IDVI value estimated for China.

***IATA data between January and March 2018, inclusive.

SAR, Special Administrative Region.

At the time of publication, much is still unknown about this aetiology of this respiratory syndrome. Enhanced surveillance at airports has been enacted in several Asian cities. There are now reports of respiratory illnesses in travellers from Wuhan under investigation in Singapore, Hong Kong and Seoul; however, to date these illnesses are not confirmed to be related to the Wuhan outbreak. Public health agencies around the world are reminding frontline healthcare providers to be vigilant for potential imported cases; however, this may be complicated in the northern hemisphere by high levels of influenza-like illnesses at this time of year. To our knowledge, no advisories against travel to Wuhan have been issued. Fortunately, most countries receiving the largest volumes of passengers from Wuhan, China appear to have high IDVI scores, corresponding to relatively strong public health and healthcare capacity. Seventeen years after the global SARS epidemic, the current outbreak in Wuhan, China serves as a reminder of how rapidly novel pathogens can appear and spread with potentially serious global consequences. Although it is unclear what the current burden of disease is or the potential for human-to-human transmission, major Asian hubs are the most probable sites of exportation should this epidemic continue, and public health officials are already on alert in those locations.

Author contributions

I.I.B., K.K. and A.W. conceived the idea. A.W., A.T.B. and C.H. conducted data analysis. I.I.B., K.K., A.W., A.T.B. and M.K. interpreted data and contributed to writing.

Conflict of interest/disclosure

K.K. is the founder of BlueDot, a social enterprise that develops digital technologies for public health. K.K., A.W., A.T.B. and C.H. are employed at BlueDot. I.I.B. has consulted for BlueDot. M.K. has no conflicts of interest to declare.
  3 in total

1.  Identification of severe acute respiratory syndrome in Canada.

Authors:  Susan M Poutanen; Donald E Low; Bonnie Henry; Sandy Finkelstein; David Rose; Karen Green; Raymond Tellier; Ryan Draker; Dena Adachi; Melissa Ayers; Adrienne K Chan; Danuta M Skowronski; Irving Salit; Andrew E Simor; Arthur S Slutsky; Patrick W Doyle; Mel Krajden; Martin Petric; Robert C Brunham; Allison J McGeer
Journal:  N Engl J Med       Date:  2003-03-31       Impact factor: 91.245

2.  Identifying Future Disease Hot Spots: Infectious Disease Vulnerability Index.

Authors:  Melinda Moore; Bill Gelfeld; Adeyemi Okunogbe; Christopher Paul
Journal:  Rand Health Q       Date:  2017-06-19

Review 3.  Human Mobility and the Global Spread of Infectious Diseases: A Focus on Air Travel.

Authors:  Aidan Findlater; Isaac I Bogoch
Journal:  Trends Parasitol       Date:  2018-07-23
  3 in total
  183 in total

1.  COVID-19 outbreak and surgeonsresponse at a Cancer Center in the United States.

Authors:  Yujiro Nishioka; Ching-Wei D Tzeng; Hop S Tran Cao; Jean-Nicolas Vauthey
Journal:  Glob Health Med       Date:  2020-04-30

2.  Hydroxychloroquine against COVID-19: A critical appraisal of the existing evidence.

Authors:  Konstantinos Tselios; Panagiotis Skendros
Journal:  Eur J Rheumatol       Date:  2020-05-15

3.  5G, Big Data, and AI for Smart City and Prevention of Virus Infection.

Authors:  Shumin Ren; Bairong Shen
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

4.  Quantifying the association between domestic travel and the exportation of novel coronavirus (2019-nCoV) cases from Wuhan, China in 2020: a correlational analysis.

Authors:  Shi Zhao; Zian Zhuang; Peihua Cao; Jinjun Ran; Daozhou Gao; Yijun Lou; Lin Yang; Yongli Cai; Weiming Wang; Daihai He; Maggie H Wang
Journal:  J Travel Med       Date:  2020-03-13       Impact factor: 8.490

5.  Experimental infection of domestic dogs and cats with SARS-CoV-2: Pathogenesis, transmission, and response to reexposure in cats.

Authors:  Angela M Bosco-Lauth; Airn E Hartwig; Stephanie M Porter; Paul W Gordy; Mary Nehring; Alex D Byas; Sue VandeWoude; Izabela K Ragan; Rachel M Maison; Richard A Bowen
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-29       Impact factor: 11.205

6.  Overview of current state of research on the application of artificial intelligence techniques for COVID-19.

Authors:  Vijay Kumar; Dilbag Singh; Manjit Kaur; Robertas Damaševičius
Journal:  PeerJ Comput Sci       Date:  2021-05-26

7.  Exploration of Association Between Respiratory Vaccinations With Infection and Mortality Rates of COVID-19.

Authors:  Deldar Morad Abdulah; Alan Bapeer Hassan
Journal:  Disaster Med Public Health Prep       Date:  2021-02-16       Impact factor: 1.385

Review 8.  COVID-19: fighting the invisible enemy with microRNAs.

Authors:  Neeraj Chauhan; Meena Jaggi; Subhash C Chauhan; Murali M Yallapu
Journal:  Expert Rev Anti Infect Ther       Date:  2020-09-16       Impact factor: 5.091

Review 9.  Animal models for SARS-CoV-2 research: A comprehensive literature review.

Authors:  Kabita Pandey; Arpan Acharya; Mahesh Mohan; Caroline L Ng; St Patrick Reid; Siddappa N Byrareddy
Journal:  Transbound Emerg Dis       Date:  2020-12-20       Impact factor: 5.005

10.  Novel coronavirus 2019-nCoV (COVID-19): early estimation of epidemiological parameters and epidemic size estimates.

Authors:  Jonathan M Read; Jessica R E Bridgen; Derek A T Cummings; Antonia Ho; Chris P Jewell
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2021-05-31       Impact factor: 6.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.